Last reviewed · How we verify
U101
U101 is a small molecule that targets the SGLT2 receptor.
U101 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | U101 |
|---|---|
| Also known as | pentosan polysulfate sodium (PPS) |
| Sponsor | TCM Biotech International Corp. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, U101 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women (PHASE3)
- Radiation Cystitis Treated With Pentosan Polysulfate Sodium Trial (PHASE2, PHASE3)
- Study of U101 for Bladder Pain and/or Urgency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- U101 CI brief — competitive landscape report
- U101 updates RSS · CI watch RSS
- TCM Biotech International Corp. portfolio CI